AN2 Therapeutics Phase 3 Trial Pause Impacts Stock
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
- Latest
- Trending
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
Tango Therapeutics receives positive coverage from Piper Sandler, emphasizing its strong position in precision oncology. The firm believes the company's ...
Novo Nordisk sees massive sales jump and expects further growth in 2024, driven by the demand for its diabetes and ...
Pharma giant Bristol Myers Squibb acquires RayzeBio for $4.1 billion, expanding its presence in the oncology sector and strengthening its ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
European companies known as GRANOLAS have proven to be a lower-risk investment, matching the growth of highflying tech giants. With ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.